Technical Analysis for KYTX - Kyverna Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 15.47 | -2.95% | -0.47 |
KYTX closed down 2.95 percent on Friday, April 26, 2024, on 1.9 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Possible NR7 | about 13 hours ago |
| 60 Minute Opening Range Breakdown | about 15 hours ago |
| Down 3% | about 15 hours ago |
| Fell Below Previous Day's Low | about 15 hours ago |
| Down 2 % | about 15 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Lupus Nephritis Sjögren Syndrome Systemic Sclerosis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Lupus Nephritis Sjögren Syndrome Systemic Sclerosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.06 |
| 52 Week Low | 15.43 |
| Average Volume | 371,663 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 24.97 |
| 20-Day Moving Average | 21.09 |
| 10-Day Moving Average | 19.08 |
| Average True Range | 1.51 |
| RSI (14) | 24.24 |
| ADX | 44.55 |
| +DI | 8.54 |
| -DI | 40.83 |
| Chandelier Exit (Long, 3 ATRs) | 21.26 |
| Chandelier Exit (Short, 3 ATRs) | 19.97 |
| Upper Bollinger Bands | 26.44 |
| Lower Bollinger Band | 15.74 |
| Percent B (%b) | -0.03 |
| BandWidth | 50.73 |
| MACD Line | -2.39 |
| MACD Signal Line | -1.88 |
| MACD Histogram | -0.5133 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.57 | ||||
| Resistance 3 (R3) | 16.67 | 16.42 | 16.38 | ||
| Resistance 2 (R2) | 16.42 | 16.14 | 16.36 | 16.32 | |
| Resistance 1 (R1) | 15.94 | 15.97 | 15.82 | 15.84 | 16.26 |
| Pivot Point | 15.69 | 15.69 | 15.62 | 15.63 | 15.69 |
| Support 1 (S1) | 15.21 | 15.41 | 15.09 | 15.11 | 14.68 |
| Support 2 (S2) | 14.96 | 15.24 | 14.90 | 14.62 | |
| Support 3 (S3) | 14.48 | 14.96 | 14.56 | ||
| Support 4 (S4) | 14.38 |
